NCT00230542已完成2 期
Phase II Study of Carboplatin and Pemetrexed in Patients With Recurrent Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 44
- 试验地点
- 3
- 主要终点
- To assess the response rate of carboplatin in combination with pemetrexed in patients with recurrent platinum-sensitive epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer.
研究概览
简要总结
The purpose of this study is to determine the effects (good and bad) the combination of carboplatin and pemetrexed have on patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
详细描述
- Before patients receive any chemotherapy treatments they will be given three medications to prevent side effects from the chemotherapy drugs. These medications are vitamin B12, folic acid and dexamethasone.
- Chemotherapy treatments will be given intravenously in the outpatient clinic. Pemetrexed will be given first and will take 10 minutes to infuse followed by carboplatin which will take 30-45 minutes to infuse. These treatments will be repeated once every three weeks for 6 cycles of chemotherapy (18 weeks).
- Before each chemotherapy treatment the following tests and procedures will be performed: physical exam and medical history; evaluation of ability to undertake daily activities; and blood tests.
- After every 2 cycles of chemotherapy (every 6 weeks) patients will have a CT or MRI scan to measure how well their cancer is responding to treatment.
- The study treatment will last for 6 cycles of chemotherapy as long as the tumor does not grow and the patient isn't experiencing any severe side effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of platinum-sensitive recurrence of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
- •The following histologic subtypes are eligible: papillary serous, endometrioid, mucinous, clear cell, adenocarcinomas, transitional, and mixtures of the above.
- •At least one measurable lesion according to RECIST criteria via CT or MRI scan
- •Received a platinum-containing regimen at initial diagnosis
- •ECOG performance status of 0,1 or 2
- •18 years of age or older
- •Life expectancy of greater than 12 weeks
- •WBC > 1,500/mm3
- •Neutrophils > 1,500/mm3
- •Platelets > 100,000/mm3
- •Total Bilirubin < 1.5 ULN
- •Calculated creatinine clearance > 45 ml/min
- •ALT/AST < 3 x ULN (no liver mets) ALT/AST < 5 x ULN (with liver mets)
- •Complete recovery from completion of previous chemotherapy or biologic therapy
- •Negative pregnancy test and agree to practice effective method of birth control
排除标准
- •Patients with sarcomatous, stromal, or germ cell elements
- •Prior pelvic radiotherapy > 25% of bone marrow
- •Uncontrolled medical problem that in the opinion of the investigator would preclude safe administration of the study drugs
- •Past history of bone marrow transplantation or stem cell support
- •Known history of CNS metastasis unless the patient has had treatment with surgery or radiation therapy, is neurologically stable, and does not require oral or intravenous corticosteroids or anticonvulsants
- •Prior malignancy except adequately treated carcinoma in situ of the uterine cervix, incidental stage I endometrial cancer, basal cell or squamous cell skin cancer or breast cancer (invasive or ductal carcinoma in situ) of which the patient has been disease-free for at least five years
- •Routine prophylactic use of G-CSF or GM-CSF or blood transfusions within 2 weeks
- •Clinically significant cardiac disease as defined by: history of unstable angina within 6 months; history of symptomatic ventricular arrhythmias; history of congestive heart failure; history of myocardial infarction within 6 months
- •Uncontrolled hypercalcemia or diabetes mellitus
- •Any signs of intestinal obstruction with bowel function and/or nutrition
- •Grade 2 or greater peripheral neuropathy
- •Participation in an investigational study within three weeks
- •History of anaphylactic shock to prior platinum chemotherapy
- •History of psychiatric disability or other central nervous system disorder
研究组 & 干预措施
Carboplatin / Pemetrexed
Experimental
Single Arm Study Carboplatin AUC 5 Pemetrexed 500 mg/m2
干预措施: Carboplatin (Drug)
Carboplatin / Pemetrexed
Experimental
Single Arm Study Carboplatin AUC 5 Pemetrexed 500 mg/m2
干预措施: Pemetrexed (Drug)
结局指标
主要结局
To assess the response rate of carboplatin in combination with pemetrexed in patients with recurrent platinum-sensitive epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer.
时间窗: 2 years
This study has now been published: Matulonis U.A.,Horowitz N, Campos S, Lee H., Lee J., Krasner C., Berlin S., Roche M., Duska L, Pereira L, Kendall D, Penson R. Phase II Study of Carboplatin and Pemetrexed for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer. J Clin Oncol. 2008:26(35):5761-6
次要结局
- To assess time to progression, progression-free survival, and overall survival in this patient population
- to assess toxicities of treatment with combination carboplatin and pemetrexed.(2 years)
研究者
Ursula A. Matulonis, MD
Medical Oncologist
Dana-Farber Cancer Institute
研究点 (3)
Loading locations...
相似试验
已完成
3 期
Study of Participants With Advanced Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung CancerNCT00948675Eli Lilly and Company361
已完成
2 期
Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly PatientsNon Small Cell Lung CancerNCT00350792Eli Lilly and Company62
已完成
2 期
Phase II study of Pemetrexed and Carboplatin plus Bevacizumab for advanced non-small cell lung cancernon-squamous non-small-cell lung cancerJPRN-UMIN000003680ippon Medical School Hospital26
终止
2 期
A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal CancerEsophageal NeoplasmsNCT00383266Washington University School of Medicine9
已完成
2 期
Phase II study of carboplatin and pemetrexed plus bevacizumab after failure of first-line EGFR TKI therapy for non-small-cell lung cancer harboring EGFR mutation.on-squamous Non-small-cell Lung CancerJPRN-UMIN000004731Central Japan Lung Study Group27